Amgen Inc. (AMGN)
Vector Securities analyst Gregory Brown raised his rating to "buy" from "neutral" after Epogen and Neupogen turned in healthy first quarter performances despite gloomy expectations. AMGN's ability to deliver healthy earnings growth makes